Загрузка...
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
BACKGROUND: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cho...
Сохранить в:
| Опубликовано в: : | Eur Heart J |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4286319/ https://ncbi.nlm.nih.gov/pubmed/25142968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehu319 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|